Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study

Takanori Numata,Hanae Miyagawa,Hironori Kawamoto,Masahiro Yoshida,Hirofumi Utsumi,Mitsuo Hashimoto,Shunsuke Minagawa,Hiromichi Hara,Jun Araya,Kazuyoshi Kuwano

Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study

2020

Takanori Numata
Hanae Miyagawa
Hironori Kawamoto
Masahiro Yoshida
Hirofumi Utsumi
Mitsuo Hashimoto
Shunsuke Minagawa
Hiromichi Hara
Jun Araya
Kazuyoshi Kuwano

Mepolizumab significantly reduces the number of annual exacerbations (AEs) and the maintenance dose of systemic corticosteroids (CSs) in patients with severe eosinophilic asthma (SEA). However, the...

Keywords:

long term learning
Mepolizumab
Body mass index
Eosinophilic asthma
Physical therapy
Pediatrics
Diabetes mellitus
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations